Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Life expectancy in glioblastoma patients who had undergone stereotactic biopsy: a retrospective single-center study

M. Halaj, O. Kalita, L. Tuckova, L. Hrabalek, M. Dolezel, J. Vrbkova

. 2024 ; 168 (4) : 349-353. [pub] 20230710

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24022790

OBJECTIVE: The best results in glioblastoma (GBM) are obtained through aggressive treatment comprising maximally radical but safe resection followed by chemoradiotherapy. However, certain patients will undergo only stereotactic biopsy. This paper aims to evaluate life expectancy in GBM patients who underwent only stereotactic biopsy, including the effect of subsequent oncological treatment. PATIENTS AND METHODS: Patients with confirmed GBM histology who had undergone stereotactic biopsy between June 2006 and December 2016 were retrospectively selected. Each patient had received a CT scan, followed by an MRI scan with a contrast agent. None of the patients were amenable to microsurgical resection. RESULTS: Of the 60 patients, 41 (69%) received no subsequent oncological treatment, while 14 (23%) underwent isolated radiotherapy. Mean survival time of all patients was 2.8 months. Those who received no additional treatment had an average survival time of 2.3 months; patients who received any type of oncological treatment was 3.7 months. Of these, those receiving radiotherapy alone had a mean survival of 3.1 months. Patients who received oncological treatment with the Stupp protocol had a survival time of 6.6 months. CONCLUSION: Diagnostic and surgical advances related to GBM treatment mean that radical resections can be performed even in eloquent brain areas. However, patients not indicated for resection will experience a major reduction in life expectancy. Patients who underwent stereotactic biopsy and received some form of oncological treatment experienced slightly increased overall survival relative to patients with a natural disease course. Patients with favorable clinical factors reacted better to treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24022790
003      
CZ-PrNML
005      
20250521143041.0
007      
ta
008      
241205s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2023.030 $2 doi
035    __
$a (PubMed)37431620
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Halaj, Matej $u Department of Neurosurgery, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0240119
245    10
$a Life expectancy in glioblastoma patients who had undergone stereotactic biopsy: a retrospective single-center study / $c M. Halaj, O. Kalita, L. Tuckova, L. Hrabalek, M. Dolezel, J. Vrbkova
520    9_
$a OBJECTIVE: The best results in glioblastoma (GBM) are obtained through aggressive treatment comprising maximally radical but safe resection followed by chemoradiotherapy. However, certain patients will undergo only stereotactic biopsy. This paper aims to evaluate life expectancy in GBM patients who underwent only stereotactic biopsy, including the effect of subsequent oncological treatment. PATIENTS AND METHODS: Patients with confirmed GBM histology who had undergone stereotactic biopsy between June 2006 and December 2016 were retrospectively selected. Each patient had received a CT scan, followed by an MRI scan with a contrast agent. None of the patients were amenable to microsurgical resection. RESULTS: Of the 60 patients, 41 (69%) received no subsequent oncological treatment, while 14 (23%) underwent isolated radiotherapy. Mean survival time of all patients was 2.8 months. Those who received no additional treatment had an average survival time of 2.3 months; patients who received any type of oncological treatment was 3.7 months. Of these, those receiving radiotherapy alone had a mean survival of 3.1 months. Patients who received oncological treatment with the Stupp protocol had a survival time of 6.6 months. CONCLUSION: Diagnostic and surgical advances related to GBM treatment mean that radical resections can be performed even in eloquent brain areas. However, patients not indicated for resection will experience a major reduction in life expectancy. Patients who underwent stereotactic biopsy and received some form of oncological treatment experienced slightly increased overall survival relative to patients with a natural disease course. Patients with favorable clinical factors reacted better to treatment.
650    _2
$a lidé $7 D006801
650    12
$a glioblastom $x mortalita $x patologie $x terapie $7 D005909
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mužské pohlaví $7 D008297
650    12
$a naděje dožití $7 D008017
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory mozku $x mortalita $x patologie $x terapie $7 D001932
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a biopsie $x metody $7 D001706
650    12
$a stereotaktické techniky $7 D013238
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a magnetická rezonanční tomografie $7 D008279
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kalita, Ondřej, $d 1972- $u Department of Neurosurgery, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Health Care Sciences, Faculty of Humanities, Tomas Bata University, Zlin, Czech Republic $7 xx0046875
700    1_
$a Tučková, Lucie $u Department of Pathology and Laboratory of Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0238007
700    1_
$a Hrabálek, Lumír $u Department of Neurosurgery, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0076898
700    1_
$a Doležel, Martin $u Department of Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0075943
700    1_
$a Vrbková, Jana, $d 1971- $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0105359
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 4 (2024), s. 349-353
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37431620 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20241205 $b ABA008
991    __
$a 20250521143039 $b ABA008
999    __
$a ok $b bmc $g 2324815 $s 1234795
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 168 $c 4 $d 349-353 $e 20230710 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK124 $a Pubmed-20241205

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...